# QR GENETICS

An AI platform using unique spatial analytics and omics datasets to generate novel drug-target combos X5 more likely to reach clinical trials

***Deliverables:*** *Communication's strategy, branding, investor deck & website, patient journey & patient recruitment strategy*

The Concept

# QR code


EC Levels
L
M
Q
H
Mask Patterns
j % 3 = 0
(i + j)%3 = 0
(i + j)%2 = 0
i % 2 = 0
((i*j)%3+i*j)%2=0
((i*j)%3+i+j)%2=0
Format error correction
Mask pattern
(i/2 + j/3)%2=0
(i*j)%2+(i*j)%3=0
Error correction level

[redacted]

L

L

E



QRGenetics

# Decoding the unknown

**Decoding the unknown**
**Decoding uniqueness**
**Revealing the code**
**Decoding genetic diseases**
**Decoding the missing link**







QRGenetics

# Decoding the unknown

We uncover new treatments for individual patients with rare diseases, enabling the identification of potential therapies for populations with common genetic diseases.



QRGenetics

# Decoding uniqueness

We uncover new treatments for individual patients with rare diseases, enabling the identification of potential therapies for populations with common genetic diseases.

QRGenetics

# Decoding the unknown

We uncover new treatments for individual patients with rare diseases, enabling the identification of potential therapies for populations with common genetic diseases.



Patient-Centered

Fast Discovery

Parallel exploration



# 4D structural modelling

Our proprietary modeling methods in conjunction with AI predictive methods. Bio Knowledge Graph represents diseases, genes, proteins, cellular pathways, symptoms and drugs networks
Unique combination of public biomedical data, scientific literature, personal patients' medical data and drug screen result.

QRGenetics

# Decoding the unknown

We uncover new treatments for individual patients with rare diseases, enabling the identification of potential therapies for populations with common genetic diseases.



## Our unique offering

We utilize a proprietary analysis method to generate insights that are used for the screening of candidate drugs for more prevalent diseases.

Patient-Centered

Fast Discovery

Parallel exploration



## 4D structural modelling

Our proprietary modeling methods in conjunction with AI predictive methods. Bio Knowledge Graph represents diseases, genes, proteins, cellular pathways, symptoms and drugs networks
Unique combination of public biomedical data, scientific literature, personal patients' medical data and drug screen result.

QRGenetics
DR. Shane Wald Altman
Co-Founder & CSO
+972.547444309
shanewa@qrgenetics.com
QRGenetics.com
QRGenetics
+972.547444309
info@qrgenetics.com
QRGenetics.com
QRGenetics
QRGenetics
+972.547444309
info@qrgenetics.com
QRGenetics.com

DR. Shane Wald Altman
Co-Founder & CSO
+972.54.7444309
shanewa@qrgenetics.com
QRGenetics.com
QRGenetics

QRGenetics
Changing the unknown

# A drug discovery engine for genetic diseases

Treating individuals with rare diseases to uncover solutions for millions

From personalized medicine for individuals to precision medicine for populations
QR genetics develop a powerful AI-supported drug discovery engine
that identifies potential therapies for common genetic diseases,
by uncovering new treatments for individual patients with similar rare disease mutations

## Our Unique Discovery Process

**01**

Patient data
Disease data
Proprietary database

Proprietary Algorithms
Disease Modeling + Protein Modeling » Target Identification + Drug Discovery

**02**

Rapid clinical validation through preclinical tests, & in human trials

**03**

Proprietary Algorithms
AI-driven Data processing to locate prevalent diseases with spatially similar functional disorders

**04**

Pre-clinical and Clinical trials in partnership with pharma or academia

## Our discovery edge

De-risking the clinical stages of drug development through in-human validation

Discovery time reduction from 3 years to 3 months

Parallel exploration of multiple diseases and drug candidates

## Autism Case Study

**PRE-TREATMENT**

7 year old

Was diagnosed with Autism spectrum disorder-level 3, caused by a point mutation that impacted his growth and development.

**POST-TREATMENT**

1-year post-treatment with a repurposed drug

Knows how to read. Can communicate with his surroundings, with friends and with family.

**DRUG INDICATION EXPANSION**

Therapy was found beneficial for

**> 100,000**

autism patients with a specific mutated protein

## Pipeline

| DRUG NAME | INDICATION TYPE | INDICATION NAME | PRE-CLINICAL | IND ENABLING | RESULTS | CLINICAL TRIAL BY ACADEMIC OR PHARMA PARTNER |
|---|---|---|---|---|---|---|
| QR-100 | Rare | Neurodevelopmental disorder (NDPLH) | | | | |
| | Comon | Autism Spectrum Disorder (ASD) | | | | |
| QR-295 | Rare | Central core disease of muscle (CCD) | | | | |
| | Comon | Myopathy | | | | |
| QR-172 | Rare | Smooth Muscle Disease | | | | |
| | Comon | Cardiomyopathy | | | | |
| | Comon | Abdominal and aortic Aneurysm | | | | |
| | Comon | Visceral myopathy | | | | |
| | Comon | Deafness | | | | |
| | Comon | Dystonia | | | | |
| | Comon | Nemaline Myopathy | | | | |
| | Comon | Basal cell carcinoma | | | | |

## Management team

**Dr. Shane Wald Altman. Ph.D.**
Co-Founder & CEO

**Prof. Miguel Weil, Ph.D.**
Co-Founder & Scientific advisor

**Dan Lavi**
Co-Founder, Entrepreneur & Business Management

**Dr. Noa Bielopolski, Ph.D.**
Director of Science

**Ido Gonen**
Co-Founder
Entrepreneur &
Business Managemen

**Dr. Noa Bielopolski, Ph.D.**
Director of Science

## Collaborators

**Prof. Arnold Levine**
P53 tumor suppressor specialist and System biologist

**Prof. Arnold Levine**
P53 tumor suppressor specialist and System biologist

## Contact us

**E.** info@qrgenetics.com
**A.** Rokach Blvd 97, Tel Aviv-Yafo
**T.** 972. 52.3442134

© All rights reserved to QRG Medical Ltd



Site by Pixelium

*" I highly recommend Pearlcom for their exceptional expertise in biotech marketing, fundraising strategy, and patient journey solutions. Caty and Chen's vast knowledge, unwavering support, and amazing collaboration skills made working with them an absolute pleasure. They actively listened to our needs, were readily available, and went above and beyond to ensure our success. Their professionalism, dedication, and profound understanding of the field make them an invaluable partner. "*

**Dr. Shane Wald Altman. Ph.D.** | Co-Founder & CEO
QRGenetics Ltd | **W.** qrgenetics.com **T.** +972 52-344-2134